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Abstract: Type 2 diabetes mellitus (T2DM) continues to rise in prevalence in the United 
States and worldwide. Despite advances in medical treatments for T2DM, many patients remain 
uncontrolled. By targeting centrally mediated pathways of glucose metabolism, bromocrip-
tine represents a novel therapeutic option in T2DM. Several small clinical trials demonstrate 
improvements in insulin resistance and glycemic control. After the submission of data from 
four recent, large clinical trials, the US Food and Drug Administration has approved the use of 
bromocriptine in T2DM. We review the available data from these four trials and other published 
studies. Bromocriptine is a promising therapy for diabetes patients and demonstrates modest 
improvements in glycemic control.
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Introduction
The rise in prevalence of type 2 diabetes mellitus (T2DM) in recent decades parallels 
the rise in obesity in both the United States and worldwide.1 It is estimated that one-third 
of individuals born in the past decade will develop T2DM.1 The cost for treatment of 
the complications of T2DM may approach one half of medical expenditures.2 Recom-
mended targeted goals can prevent complications and improve outcomes, but these are 
only met by 50% to 70% of individuals with T2DM despite current therapies.3
The treatment options for T2DM have also increased over the past 15 years. As we 
begin to understand some of the underlying pathophysiology in T2DM, our pharma-
cologic repertoire has expanded to target novel physiologic mechanisms.4 Still, many 
patients remain uncontrolled and the effectiveness of current therapies wanes over 
time.5,6 Newer classes of medical treatments for T2DM are promising for modification 
of disease progression, but they are expensive and there is little experience with use 
of these agents over the long term.4,7
Bromocriptine has been in clinical use for over 30 years.8 The utility of bromocrip-
tine in diabetes patients has been proposed more recently, based on its activity in 
modulating central glucose and energy metabolism pathways.9 After several recent 
clinical trials, bromocriptine was approved by the United States Food and Drug 
Administration (FDA) for use in T2DM.10,11 The purpose of this paper is to review 
the current literature on the effects of bromocriptine (under the trade name Cycloset®; 
  Veroscience, Tiverton, RI) in diabetes patients, including a proposed mechanism of 
action, a summary of the clinical trials in humans, and a discussion of safety and toler-
ability issues. Bromocriptine holds promise to be an effective treatment for T2DM.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 44
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Mechanism of action
Bromocriptine is derived from an ergot alkaloid and functions 
as a postsynaptic dopamine receptor agonist and serotonin 
modulator.12 Clinically, bromocriptine is used to treat 
Parkinson’s disease through activity at dopamine receptors 
in the nigrostriatal tract and to treat hyperprolactinemia and 
acromegaly via tuberoinfundibular pathways.12
Glucose and energy metabolism is tightly regulated by 
the central nervous system (CNS) mainly at centers in the 
medial basal hypothalamus.13 The CNS regulates hepatic 
glucose production through sympathetic pathways and 
integrates information on fuel availability through leptin, 
ghrelin, insulin, glucagon-like pepide-1 (GLP-1) and other 
hormonal signals. Diabetic and obese patients have impaired 
responses to these signal pathways and display elevations in 
hepatic glucose production, insulin resistance and impaired 
pancreatic β-cell function.7
The metabolic control pathways of the CNS are modu-
lated, in part, by dopaminergic signaling. Agents that block 
dopamine activity, such as antipsychotic medications, are 
associated with impaired metabolism, weight gain, insu-
lin resistance and dyslipidemia.14 To achieve the opposite 
effect, dopamine agonist therapy with bromocriptine has 
been proposed as a means of improving glucose and energy 
metabolism through activation of CNS dopaminergic path-
ways responsible for metabolic control.9
Multiple animal studies demonstrate metabolic improve-
ments after the administration of bromocriptine including 
significant weight loss, decreased levels of blood glucose 
and triglycerides, decreased insulin resistance and increased 
glucose tolerance.15–19 Human studies show similar effects, 
though the results are not as profound.20–25 Dosages of 
bromocriptine in human trials have ranged from 2.5 mg 
to 5 mg per day. A rapid release form of bromocriptine 
(RR-bromocriptine; Cycloset®) is used in several of these 
trials, dosed at 4.8 mg per day.11,20,21,23
The pharmacological activity of bromocriptine occurs 
mainly through activation of D2 receptors and inhibition 
of D1 receptors in the CNS.26 Bromocriptine also exhibits 
  activity at serotonin receptors including inhibition of 
5-HT2A and partial agonism of 5-HT2B receptors.27 The exact 
  mechanism by which these pathways modulate glucose and 
energy metabolism remains to be elucidated.
Published clinical trials
In the current literature, there are 6 clinical trials using 
bromocriptine therapy for the treatment of T2DM and/or 
obesity.20–25 The results of these studies are summarized in 
Table 1 and reviewed below.
The first clinical study investigating the metabolic effects 
of bromocriptine was performed in 1992.24 In this observa-
tional trial, 33 non-diabetes obese subjects and 15 diabetes 
subjects were given bromocriptine 2.5 mg daily and followed 
weekly for 4 to 8 weeks. In the diabetes group, fasting glu-
cose decreased from 283 mg/dL to 184 mg/dL in subjects 
on insulin regimens, while fasting glucose levels decreased 
from 231 to 166 for those who were on oral hypoglycemic 
regimens. The mean weight loss was 1.1 kg in the diabetes 
group.
A second observational study followed 13 obese non-
diabetes female subjects with hyperinsulinemia after 8 weeks 
of open-label therapy with RR-bromocriptine, 4.8 mg daily.23 
At baseline and again at the study endpoint, hourly plasma 
glucose, insulin, triglyceride and free fatty acid concentra-
tions were measured over a 24-hour period in each subject. 
A slight, but significant (P  0.05) decrease was noted in 
Table 1 Summary of published clinical trials
Study  Subjects  n  Bromocriptine Duration Results – change in
Dosage (Weeks) Fasting BG (mg/dL) HbA1c (%) Weight
Observational trials
Meier et al24 OB 33 1.25 mg daily 6 NA NA -2.3 kg
DM2 15 2.5 mg daily 4–8 -99 insulin group NA -1.1 kg
-65 oral agent group
Kamath et al23 OB 13 4.8 mg daily 8 no change NA NA
Randomized trials
Cincotta et al20 OB 17 1.6 to 2.4 mg daily 18 no change NA -6.3 kg
Pijl et al21 DM2 22 4.8 mg daily 16 -28 -0.6 no change
Aminorroaya et al22 DM2 40 2.5 mg daily 12 -27 -0.4 no change
Wasada et al25 DM2 13 2.5 mg 2 × daily 30 no change NA no change
Abbreviations: DM2, type 2 diabetics; OB, obese non-diabetics; HbA1c, glycosylated hemoglobin; BG, blood glucose; NA, data not available.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 45
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plasma glucose, triglycerides and free fatty acids. The degree 
of change in plasma glucose was less than 18 mg/dL, and 
only observed in a 3-hour period after lunch. There was no 
significant change in the 24-hour insulin levels.
Cincotta et al, conducted a double blind, placebo-
  controlled trial of RR-bromocriptine in 17 obese subjects with 
impaired glucose tolerance, of which 5 had diabetes.20 Daily 
dosages ranged from 1.6 to 2.4 mg in the eight patients who 
received RR-bromocriptine. After 18 weeks of follow up, 
the RR-bromocriptine group demonstrated significant weight 
loss of 6.3 ± 1.5 kg (P  0.01) and had a 46% decrease in 
area under the serum glucose curve during an oral glucose 
tolerance test (P  0.02) compared to baseline. No changes 
were noted in the placebo group.
Two double-blind, placebo-controlled trials that 
  investigate the use of RR-bromocriptine in obese patients 
with T2DM show significant metabolic improvements.21,22 
The first trial enrolled 22 subjects that were followed for 
16 weeks.21 At the study endpoint, fasting plasma glucose 
decreased by 17 mg/dL, mean change in plasma glucose 
after oral glucose tolerance testing decreased by 22 mg/dL 
and glycosylated hemoglobin (HbA1c) was reduced by 0.6% 
compared to placebo. The second trial enrolled 40 subjects 
that were followed for 3 months.22 Fasting plasma glucose 
decreased by 27 mg/dL and HbA1c remained unchanged, 
  compared to an HbA1c increase by 1.1% in the placebo 
group.
A third double-blind, placebo-controlled trial was 
conducted using twice daily dosing of bromocriptine in 
13 obese diabetes patients.25 The study drug in this trial 
was not a rapid release form of bromocriptine. After 6 to 
8 months, there were no significant changes in percent body 
fat, visceral fat or in the homeostasis model assessment of 
insulin resistance following a standardized meal. HbA1c 
was not measured.
The results from these 6 trials in humans show moderate 
improvements in glycemic control and in metabolic markers 
using RR-bromocriptine to treat patients with T2DM. These 
studies are relatively brief and enroll a small number of 
patients. Most of the studies required run in periods with 
dose increases of RR-bromocriptine on a weekly basis, which 
further shortens the length of optimal RR-bromocriptine 
exposure. Studies with longer term follow up may show 
additional benefits.
The formulation of bromocriptine is also important. 
In these clinical studies, 5 out of 6 studies that showed 
clinical benefits used RR-bromocriptine.20–24 The one study 
that used an ordinary form of bromocriptine showed no 
benefit.25 Since “fine tuning” seems important for effects on 
hypothalamic circadian rhythm, RR-bromocriptine may be 
required to meet the concept and hypothesis of improved 
glucose and energy metabolism through CNS mediation.
Clinical trials of RR-bromocriptine 
for FDA approval
The results of several relatively large clinical trials have 
prompted the FDA to approve RR-bromocriptine for use in 
T2DM.11,28,29 These studies have yet to be formally published. 
We summarize their results from available sources.
A single clinical trial using RR-bromocriptine to 
treat T2DM was presented at the 2008 annual meeting 
of the American Diabetes Association (ADA).10 In this 
study, 3070 diabetes subjects were randomized to receive 
RR-bromocriptine or placebo (2:1) in addition to their usual 
diabetes therapy. The authors report a 42% relative reduc-
tion in cardiovascular events with use of RR-bromocriptine 
(P = 0.036; 1.5% RR-bromocriptine vs 2.96% placebo event 
rate) at 52-week follow up. It should be noted, however, 
that there were significant baseline differences in the two 
groups including increased rates of cardiac revascularization 
procedures and increased rates of stroke in the placebo group 
before the trial started. Whether these baseline differences 
contributed to the overall study outcome requires further 
investigation.
A second presentation was given at the 2009 ADA meet-
ing that analyzed markers of glycemic control in this same 
trial, focusing only on the subgroup of participants who were 
failing thiazolidinedione therapy (n = 52 RR-bromocriptine 
group; n = 68 placebo group). After 1 year, levels of HbA1c 
were lower in the RR-bromocriptine group compared to 
  placebo. For subjects with baseline HbA1c  8.5% or  7.5%, 
treatment with RR-bromocriptine decreased HbA1c by 1.21% 
(P  0.05) and 0.57% (P  0.05) compared to placebo, 
respectively.29
The results of this 52-week trial have yet to be formally 
published. The same group has performed three other 
24-week trials using RR-bromocriptine to treat T2DM. 
Results from these three trials are also unpublished, but are 
summarized online.28
The first 24-week trial used RR-bromocriptine monother-
apy or placebo monotherapy in 159 patients with uncontrolled 
T2DM. After 24 weeks, HbA1c decreased by 0.1% in the 
RR-bromocriptine group (baseline HbA1c = 9.0%) versus a 
0.3% increase in the placebo group (P  0.05).28
The second 24-week trial, “Study L”, involved 249 T2DM 
patients inadequately controlled on sulfonylurea therapy. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 46
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Enrolled subjects were given RR-bromocriptine or placebo 
in addition to their current medication. After 24 weeks, HbA1c 
decreased by 0.4% in the RR-bromocriptine group (baseline 
HbA1c = 9.0%) versus a 0.3% increase in the placebo group 
(P  0.001).28
The third 24-week trial, “Study K”, enrolled 245 patients 
with T2DM that were also inadequately treated with sulfonyl-
urea therapy. Enrolled subjects were given RR-bromocriptine 
or placebo in addition to their current medication. After 
24 weeks, HbA1c decreased by 0.1% in the RR-bromocriptine 
group (baseline HbA1c = 9.3%) versus a 0.4% increase in the 
placebo group (P  0.001).28
The results of these four studies served as the basis for 
the FDA approval of RR-bromocriptine for the treatment of 
T2DM. While the apparent results of these trials are statistically 
significant, the small improvements seen in diabetes control 
may only have a modest clinical impact. The observed decrease 
in cardiovascular outcomes seen with RR-bromocriptine in the 
52-week trial may be the result of poor randomization. As of 
January, 2010, none of these four trials have been published 
in peer reviewed journals. Further scrutiny of these trials is 
warranted and we anxiously await their publication.
Pharmacokinetics
The peak activity of RR-bromocriptine (Cycloset®) occurs 
1 to 3 hours following oral ingestion and its plasma half-life 
is approximately 15 hours.12 The vast majority (90%–96%) 
of circulating bromocriptine is protein-bound.12 Due to this 
relatively short half-life, bromocriptine is often admin-
istered in divided doses for the treatment of Parkinson’s 
disease or hyperprolactinemia, usually 2 to 3 times daily.26 
In the human trials of diabetes patients, RR-bromocriptine 
is given as a once-daily morning dose.20–25 Daily cycling of 
dopamine agonism may be important for improvements in 
glycemic control.21
Bromocriptine is metabolized in the liver by the 
CYP3A4 cytochrome system. Medications that inhibit this 
pathway, such as macrolide antibiotics, protease inhibi-
tors or anti-fungal therapies will raise circulating levels 
of bromocriptine.12 Inducers of CYP3A4 activity, such as 
phenytoin or St. John’s wort, decrease bromocriptine levels 
and can lead to ineffectiveness of therapy.12
Safety of bromocriptine
The accumulated data from 3 decades of clinical trials 
and post-marketing analysis in patients with Parkinson’s 
disease, hyperprolactinemia, and acromegaly treated with 
bromocriptine demonstrate relative safe use. Serious events 
are uncommon and usually occur at high cumulative doses. 
The most common side effects of bromocriptine are benign: 
nausea, vomiting, dizziness, hypotension, headache, and 
fatigue.8,30,31 More serious side effects are rare and include 
psychosis, fibrosis (retroperitoneal, pleural, cardiac valve), 
and cardiovascular events (myocardial infarction, stroke).31 
The post-marketing reports of fibrosis events involve higher 
doses of bromocriptine.32 With regards to the adverse 
cardiac effects, bromocriptine demonstrates substantially 
lower risk than cabergoline, another commonly prescribed 
  dopaminergic agent.33,34
RR-bromocriptine use in T2DM differs from typical 
  bromocriptine therapy in the aforementioned conditions. 
Thus, it is possible that the side effect profile used T2DM may 
differ. However, the dose approved for treatment of T2DM 
is 2- to 3-fold lower than usual doses in hyperprolactinemia 
and 10- to 20-fold lower than treatment for Parkinson’s 
disease. These relatively low doses for treatment of T2DM 
may reduce the risk of adverse effects. On the other hand, 
it is possible that the RR-bromocriptine may increase the 
risk and/or severity of side effects as compared to typical 
bromocriptine or modified release bromocriptine (Parlodel®; 
Novartis) preparations.
Side effect and safety data of RR-bromocriptine in 
T2DM are available from two 6-month trials and a 1-year 
safety trial.10,20,23 At this time, available post-marketing data 
are limited.
Overall, RR-bromocriptine demonstrates good safety 
and tolerability. Gastrointestinal side effects are among 
the most common reported adverse events, which include 
nausea in 26% to 33% and vomiting in 5% to 8% of 
subjects. Dizziness is another common side effect, and is 
reported in 12% to 15% of subjects. Discontinuation of 
RR-bromocriptine due to adverse reactions was mainly attrib-
utable to nausea and less frequently to dizziness. Thirteen 
percent of RR-bromocriptine users withdrew from a mono-
therapy trial and add-on to sulfonylurea trial, compared to 
placebo withdrawal of 3% (P  0.00001) and 5% (P = NS).9 
Orthostatic hypotension and syncope are less common. 
Asthenia or weakness occurred in 15%, headache in 11% 
to 17%, fatigue in 14%, and constipation in 6% to 11% of 
subjects.9,10 These side effects tend to present on initiation or 
titration of RR-bromocriptine, and appear to be minimized 
by gradual weekly titration.
To fulfill FDA requirements and demonstrate drug 
safety, Scranton et al, conducted an industry sponsored 
trial that examined the overall safety, cardiovascular safety, 
and efficacy of RR-bromocriptine for treatment of T2DM. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 47
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The study included 3070 patients with a 1-year follow up 
period.10,11 Adverse events were reported in 8.5% in the 
RR-bromocriptine group of 9.6% of placebo group (P = NS). 
Rates of hypoglycemia were similar in RR-bromocriptine 
users compared to placebo. Reported hypoglycemia occurred 
in 2.5% of those on RR-bromocriptine monotherapy, 8.6% in 
combination with sulfonylurea, and 6.9% as add on therapy. 
Severe hypoglycemia (blood glucose 50 mg/dL and 
neurologic symptoms requiring assistance with treatment) 
occurred in 0.5% of RR-bromocriptine users compared to 
1% of placebo group.11
To date, there have been no serious adverse events 
(fibrosis or psychosis) reported in bromocriptine or RR-
bromocriptine use in T2DM. These effects are much less 
common with bromocriptine therapy compared with the use 
of other ergot-derived agents, however there may be potential 
for low dose RR-bromocriptine to cause fibrosis.33–35 Long-
term studies are needed to assess the cumulative dosage 
safety of RR-bromocryptine.
Patient adherence
Despite well-established guidelines for glycemic control, 
many diabetes patients do not achieve targeted goals.3 Adher-
ence to prescribed medicine, dietary and lifestyle regimens 
are all crucial factors in T2DM management. Diabetes 
patients often cite medication cost, forgetfulness to take 
medications, comorbid depression and concern for weight 
gain, hypoglycemia or other adverse effects as reasons for 
nonadherence to prescribed medication regimens.36
With regard to these factors, RR-bromocriptine has 
advantages over other new and existing diabetes therapies. 
For patients who do not always remember to take their 
medications, the once-daily dosing schedule of bromocriptine 
fits easily into most daily routines, which may aid in medi-
cation adherence. However, adherence may be reduced by 
the 6-tablet (0.8 mg each) optimal dose that is approved for 
treatment of T2DM.
Bromocriptine has several other clinical properties that 
are favorable to diabetes patients. Therapy with bromocrip-
tine is associated with a small degree of weight loss and is 
not associated with increased rates of hypoglycemia or weight 
gain.20–25 Bromocriptine also causes mild decreases in blood 
pressure by 3 to 7 mmHg systolic,8,30,37 which may be helpful 
as the majority of diabetes patients are hypertensive.38 Some 
authors argue that dopamine agonists such as bromocriptine 
have beneficial effects on depression,39 which also has a high 
prevalence in the diabetes population and is associated with 
poor glycemic control.36
The mild adverse effects discussed above may limit its 
use in certain patients. Approximately 50% of treated patients 
experience one of the common, benign adverse effects, which 
usually do not lead to discontinuation of therapy.8,30
The trials for bromocriptine use in T2DM show a near 
100% adherence rate confirmed by suppression of pro-
lactin levels.20–25 However, some patients were unable to 
achieve dosage targets. In trials investigating the treatment 
of Parkinson’s disease and hyperprolactinemia, patients 
also demonstrate a high degree of adherence (96%–98%) 
despite multiple daily dosages of bromocriptine.8,37 
 In general, bromocriptine is well tolerated and most individu-
als are adherent to therapy. An advantage of bromocriptine 
over other diabetes medications is that adherence can be 
assessed directly by measuring serum prolactin.
Conclusion
Although in clinical use for other indications for over 
30 years, bromocriptine represents a novel agent that targets 
a unique pathway in the management of T2DM. While the 
exact mechanism remains to be elucidated, the known activity 
of bromocriptine through dopamine agonism may modulate 
CNS regulatory pathways of glucose and energy metabo-
lism. A number of small clinical trials have shown modest 
improvements in glycemic control using RR-bromocriptine. 
Larger, unpublished trials seem to confirm mild benefits using 
RR-bromocriptine in T2DM patients.
Presently, it is not clear how RR-bromocriptine would fit 
in the current recommended strategy for medical treatment of 
diabetes.3 We speculate that bromocriptine may have optimal 
effects if used early in the course of the disease, possibly in 
combination with other potential disease-modifying therapies 
such as metformin, thiazolidinediones, or GLP-1 agonists. 
However, since a subgroup analysis showed benefit in 
patients who were failing therapy with thiazolidinediones,29 
RR-bromocriptine may have utility later in the course of 
T2DM as well. We await publication of several large trials 
to confirm the potential benefits of RR-bromocriptine for 
diabetes patients.10,11
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